BEAM Beam Therapeutics
- 21.380
- -0.220-1.02%
- 21.570
- +0.190+0.89%
Beam Therapeutics News
Beam Therapeutics Analyst Ratings
Beam Therapeutics: A Buy Rating Amidst Gene Editing Industry Developments
Beam Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)
Beam Therapeutics: Financial and Clinical Prospects Inform Hold Rating
Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating
Beam Therapeutics Analyst Ratings
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR), Beam Therapeutics (BEAM) and Opko Health (OPK)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Beam Therapeutics (BEAM), ACADIA Pharmaceuticals (ACAD) and Recursion Pharmaceuticals (RXRX)
Beam Therapeutics: Strong Buy Rating on Impressive Q4 Earnings and Promising Pipeline Developments
Barclays Reaffirms Their Hold Rating on Beam Therapeutics (BEAM)
William Blair Keeps Their Buy Rating on Beam Therapeutics (BEAM)
Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating
JP Morgan Upgrades Beam to Overweight, Cites AATD Therapy Potential
Beam Therapeutics Analyst Ratings
BMO Capital Sticks to Its Buy Rating for Beam Therapeutics (BEAM)
B of A Securities Downgrades Beam Therapeutics to Neutral, Announces $35 Price Target
Beam Therapeutics Analyst Ratings
Jefferies Downgrades Beam Therapeutics to Hold, Lowers Price Target to $30
Analysis
Price Target
No Data
